Benchmark Reiterates Buy Rating on Emergent BioSolutions (EBS)

June 2, 2026 8:40 AM

Benchmark analyst Robert Wasserman reiterated a Buy rating and $12.00 price target on Emergent BioSolutions (NYSE: EBS).The analyst commented, "Emergent ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found